Table 1. Patient characteristics of the entire population.
| Characteristics | Subtypes | All patients (N=129) |
|---|---|---|
| Age, median [range], year | 72 [43–86] | |
| Sex, n (%) | Male | 91 (70.5) |
| Female | 38 (29.5) | |
| Smoking, n (%) | Ever | 96 (74.4) |
| Never | 33 (25.6) | |
| PS, n (%) | 0–1 | 98 (76.0) |
| ≥2 | 31 (24.0) | |
| Stage, n (%) | III | 3 (2.3) |
| IV | 95 (73.6) | |
| Recurrent | 31 (24.0) | |
| Pathology, n (%) | Adenocarcinoma | 113 (87.6) |
| Other | 16 (12.4) | |
| TTF-1, n (%) | Positive | 96 (74.4) |
| Negative | 33 (25.6) | |
| PD-L1, n (%) | <1% | 46 (35.7) |
| 1–49% | 39 (30.2) | |
| ≥50% | 44 (34.1) | |
| EGFR, n (%) | Positive | 20 (15.5) |
| Negative | 109 (84.5) | |
| ALK, n (%) | Positive | 3 (2.3) |
| Negative | 126 (97.7) | |
| Regimen, n (%) | ICI | 70 (54.3) |
| ICI + chemo | 59 (45.7) |
PS, performance status; TTF-1, thyroid transcription factor-1; PD-L1, programmed death ligand-1; EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase; chemo, chemotherapy; ICI, immune checkpoint inhibitor.